CLDX Celldex Therapeutics Inc.

2.29
-0.1  -4%
Previous Close 2.39
Open 2.57
Price To Book 0.31
Market Cap 34,392,603
Shares 15,018,604
Volume 240,558
Short Ratio
Av. Daily Volume 130,061
Stock charts supplied by TradingView

NewsSee all news

  1. Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

    HAMPTON, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019. "Celldex achieved a

  2. Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

    -CDX-0159 IND accepted; Phase 1 study to start by YE 2019--CDX-527 on track for IND filing in 1H 2020- HAMPTON, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the

  3. CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

    -Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study--Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity--Clinical trial collaboration with Merck

  4. Celldex Therapeutics Announces Upcoming Data Presentations

    HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and

  5. Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

    HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data ASCO June 1, 2019 noted 2/19 CRs + one PR.
CDX-3379
Recurrent/metastatic head and neck squamous cell cancer
Phase 1/2 data presented November 17, 2018 at the Society for Neuro-oncology (SNO) Meeting.
Varlilumab and nivolumab
Solid tumors - cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b data released April 16, 2018 - primary endpoint not met.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 presentation at AACR April 15, 2018.
CDX-301
Non-small Cell Lung Cancer (NSCLC)
Phase 1 presentation at SITC November 7, 2019.
CDX-1140
Solid tumors

Latest News

  1. Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

    HAMPTON, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019. "Celldex achieved a

  2. Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

    -CDX-0159 IND accepted; Phase 1 study to start by YE 2019--CDX-527 on track for IND filing in 1H 2020- HAMPTON, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the

  3. CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

    -Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study--Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity--Clinical trial collaboration with Merck

  4. Celldex Therapeutics Announces Upcoming Data Presentations

    HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and

  5. Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

    HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder,